UBS Group downgraded Varian Medical Systems from to In-Line

UBS Group downgraded Varian Medical Systems from Buy to In-Line

UBS Group reiterated coverage of Varian Medical Systems with a rating of In-Line and set a new price target of $1.00

SC 13G/A - VARIAN MEDICAL SYSTEMS INC (0000203527) (Subject)

PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Varian, a Siemens Healthineers company, announced today that cancer patients in Australia will be the first in the world to benefit from streamlined, coordinated cancer care facilitated by an upcoming release of the ARIA® oncology information system (OIS) with new multi-disciplinary functionality. Australia's Icon Group will become the first in the world to deploy this new system, which is scheduled for release in Australia and other global sites in early 2022. Icon plans to go live with its first location in 2022. After a successful deployment, the new ARIA system will serve as Icon's next-generation platform for enhancing clinical operatio

PALO ALTO, Calif., April 27, 2021 /PRNewswire/ -- Varian (NYSE:VAR), a Siemens Healthineers company, has signed an agreement with Australia's Icon Group to provide 30 linear accelerators and associated treatment software to help tackle the growing global cancer burden. This agreement further strengthens the global partnership between Varian and Icon Group, together increasing access to care across regional and underserviced areas in Australia and Asia. The order is comprised of a variety of Varian linear accelerators and software including Halcyon™, TrueBeam®, and HyperArc™. These systems will be installed in new and existing Icon cancer centers in Australia to increase capacity and broaden

NEW YORK, April 15, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the open of trading on Tuesday, April 20: S&P MidCap 400 constituent PTC Inc. (NASD:PTC) will replace Varian Medical Systems Inc. (NYSE:VAR) in the S&P 500, and Lattice Semiconductor Co. (NASD:LSCC) will replace PTC in the S&P MidCap 400. Siemens Healthineers AG (XETR: SHL) acquired Varian Medical Systems Inc. in a deal that closed today, April 15. Progyny Inc. (NASD:PGNY) will replace Domtar Corp. (NYSE:UFS) in the S&P MidCap 400, and Domtar will replace NIC Inc. (NASD:EGOV) in the S&P SmallCap 600. S&P 500 constituent Tyler T

PALO ALTO, Calif., April 12, 2021 /PRNewswire/ -- Varian (NYSE:VAR) today announced it received the Best After-Sales Service Award for Radiotherapy Products in the 2020 Chinese Medical Devices Industry Data and After-Sales Service Survey for the fourth year in a row. Varian's Net Promoter Score improved by 7.3 percentage points from 2019 to 2020. In the annual survey results, Varian ranked first in the following 10 categories: Net Promoter Score; Market Share; Satisfaction; Satisfaction in Grade A Hospitals; Product Quality; Services Quality; Services Attitude; Efficiency; Training; and Parts Delivery Time. These survey results demonstrate Varian's ongoing commitment to its customers throug

PALO ALTO, Calif., April 8, 2021 /PRNewswire/ -- Varian (NYSE: VAR) today announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation—a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow. Organ segmentation is the process of identifying the organs and tissues in diagnostic images that must be targeted or protected during a course of radiation

PALO ALTO, Calif. and PETACH TIKVA, Israel, March 25, 2021 /PRNewswire/ -- Varian (NYSE: VAR) today announced a new investment in Bend It Technologies Ltd., a medical device company based in Petach Tikva, Israel, that is developing the Bendit® steerable microcatheters for use by interventionalists performing minimally-invasive peripheral vascular procedures. They can be used to deliver diagnostic, embolic, or therapeutical materials into the vasculature. "The Bendit catheters' unique design brings 3D steerability to a new dimension in microcatheter technologies, providing interventional radiologists with control of the catheter tip and tip shape to successfully navigate even the most tortuou

PALO ALTO, Calif., March 2, 2021 /PRNewswire/ -- Varian (NYSE: VAR) today announced that Chief Executive Officer Dow Wilson, after more than 16 years with the Company, will retire upon the successful completion of the proposed combination of Varian and Siemens Healthineers AG (Frankfurt: SHL). Wilson will be succeeded by Chris Toth, President and Chief Operating Officer of Varian, who will become CEO of the Varian business segment of Siemens Healthineers upon the transaction close. Toth will report directly to Dr. Bernd Montag, Chief Executive Officer of Siemens Healthineers. In connection with the completion of the transaction, which is expected to occur in the first half of calendar year

PALO ALTO, Calif., Feb. 18, 2021 /PRNewswire/ -- Varian (NYSE: VAR) announced it has joined the Cancer Drug Development Forum (CDDF) as an industry partner. This makes Varian the first medical technology company to join CDDF, the leading non-competitive drug development platform in Europe. CDDF's objective is to stimulate advancement in cancer drug development and access. CDDF's integrative approach brings together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups to improve cancer treatment. Varian is joining the CDDF Industry Partners Platform to support and expand its mission by combining the a

PALO ALTO, Calif., Feb. 4, 2021 /PRNewswire/ -- Varian (NYSE: VAR) has started the installation of the cyclotron and gantry for its ProBeam® 360° single-room proton therapy system at Penn Medicine Lancaster General Health's Ann B. Barshinger Cancer Institute. The cyclotron and gantry are core pieces of equipment of the ProBeam® 360° system. The Ann B. Barshinger Cancer Institute, which is part of Penn Medicine Lancaster General Health, has become the first treatment center in the world to have a ProBeam® 360° system from Varian. The center is expected to treat its first patients in 2022. "Varian is proud of our longstanding collaboration with Penn Medicine, which goes back decades and e

PALO ALTO, Calif., Jan. 26, 2021 /PRNewswire/ -- First Quarter 2021 Summary Oncology Systems gross orders grew 2% in dollars or 1% in constant currency in the quarter; trailing twelve months gross orders down 5% in dollars or 6% in constant currency 13 EthosTM orders received, including 8 in the Americas, 4 in EMEA, and 1 in Asia-Pacific 1 Proton order awarded in China Total company revenues down 6% in dollars, or 8% in constant currency, to $779 million GAAP operating earnings grew 7% at 15.1% of revenues; non-GAAP operating earnings grew 1% at 17.5% of revenues GAAP net earnings per diluted share of $1.05; non-GAAP net earnings per diluted share of $1.14 Cash flows from operation

15-12B - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

25-NSE - VARIAN MEDICAL SYSTEMS INC (0000203527) (Subject)

S-8 POS - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

S-8 POS - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

S-8 POS - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

S-8 POS - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

8-K - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

8-K - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

8-K - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

8-K - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)